Trellis Vitality Review: One Honest Table, Four Missing Ones

Trellis Vitality publishes the best-formed GLP-1 price table of any operator we screened this August: an actual rendered table, three columns wide, sitting on the program page where anyone can read it without an account. It also publishes four other programs whose entire price disclosure is the phrase "starting at", followed by one number and no ladder at all. Both of those facts are about the same company, and holding them together is what this review is for.

The table that is genuinely good

Compounded semaglutide is $150 a month on a one-month plan, $140 a month on three, $133 a month on six. Tirzepatide is $199, $189 and $179 across the same three terms. The page labels the column explicitly — a per-month price, with longer plans costing less per month — and states that all dosages are available at the same price, so titrating upward does not move you into a new bracket.

The single most important thing here is that the one-month column is unambiguously the month-to-month rung. That is not a given. The recurring failure across this market is a six-month prepay total, divided by six, printed as though it were a monthly rate — and a reader who signs up on that figure discovers the commitment only at checkout. Trellis prints three terms side by side and lets you see the trade. It is the honest shape, and $150 is a genuinely competitive number for it.

The four programs with no table

Then you click through to anything else.

NAD+ — the flagship, judging by how the site talks about itself — is priced as "treatment plans starting at $129/month". Glutathione is "starting at $93/month". Lipo-MIC with B12 is "starting at $130/month". Tesamorelin is "starting at $299/month". That is the whole disclosure. There is no rung table on any of those pages.

We looked for one properly before saying so. We pulled the site's own build script for product detail pages — seven kilobytes, containing no pricing. We read the rendered page HTML. We went as far as the intake flow the enrollment button leads to and read what the server sends it, which carries store theming and questionnaire metadata and no product prices. There is no ladder behind those four figures anywhere we could reach.

So we will not publish $129 as Trellis's monthly NAD+ price, and neither should anyone else. Here is what we can say instead, and the distinction is the whole point: the disclosed figure is "from $129 a month, full ladder not published."

We can also say what we suspect, clearly labeled as suspicion. On the GLP-1 line, the six-month rung sits about 12% below the one-month rung. If the other four programs are built the same way — and there is no reason to think a company would use two different pricing architectures internally — then $129, $93, $130 and $299 are most likely the longest-prepay rungs, and the month-to-month figures are higher. That is an inference from one page's structure, not an observation of the other four. We are recording it as unverified and you should treat it that way.

A claim on the company's own blog that the company's own pages do not support

Trellis's blog, in a post about NAD+ injection cost updated in July 2026, states twice that Trellis publishes its complete pricing on the program page.

It does not. The GLP-1 program page does. The NAD+ program page — the page that post is about — publishes one "starting at" number and nothing else.

We are flagging this rather than letting it pass because of what this publication is for. A gap between what a company charges and what it says it charges is a pricing problem. A gap between a company's transparency claim and its transparency practice is a different and slightly worse problem, because the claim is what a reader uses to decide they do not need to check. On the axis we grade — can a stranger read the price — Trellis earns a high mark for its GLP-1 page and then spends some of it here.

The numbers we are deliberately not repeating

The site carries a 4.7-out-of-5 rating, a current-patient count in the thousands, an average number of weeks saved, and an average annual saving per patient. None of them is sourced anywhere on the site — no review platform, no methodology, no denominator.

We are telling you they exist and declining to reprint any of them. An unsourced average saving is a marketing figure, and repeating it in a review is how a marketing figure becomes a fact with a citation to us. If Trellis publishes the working behind those numbers, we will read it.

Who prescribes, and who compounds

The clinical work is done by Arora Health & Aesthetics, LLC, whose medical director is Dr. Sean Arora. His NPI, 1841729449, resolves in the national registry to an active Family Medicine record in Seattle, Washington.²

If The Edit is also on your shortlist, this is the paragraph to slow down on: it is the same medical group and the same medical director. The pharmacies differ, the prices differ, and the two are separable products — but they are not two independent clinical opinions, and shortlisting both does not give you the second look you think it does. The same sentence appears in our review of The Edit.

The pharmacy is VialsRX, a state-licensed compounding pharmacy in Houston, Texas — named, which most of this cohort does not do. Naming your compounder is the disclosure that matters most for a compounded medicine, and Trellis makes it.

What is not disclosed is the legal entity. The terms page is about three kilobytes of text and names no LLC or corporation behind the brand, so there is no company name to look up in a state register. The site says it operates in all fifty states and that there is no membership fee and no consult cost, with a free assessment — none of which is corroborated in a terms document, because the terms document is too thin to corroborate anything.

The regulatory screen

We queried the FDA's live warning-letter index for the brand, for its medical group and for its named pharmacy. Nothing matched in the company column.³ As with every screen in this batch, the pass carried a positive control — a company with a known 2026 letter, which returned correctly — because a query that has silently broken looks exactly like a clean result.

What this has to do with a gut-health publication

We cover prescription GLP-1 programs here for one reason: they are the intervention our readers are most often weighing against, or alongside, the food-and-fiber approach that fills the rest of this library. The molecules work — once-weekly tirzepatide produced substantially greater mean weight loss than placebo in its pivotal obesity trial⁴ — and the reason people stop is very often gastrointestinal rather than financial.⁵

Which is worth pricing in before you take a six-month rung to save 12%. A prepay term is a bet on your own tolerance. If you have not yet found out how your gut handles a GLP-1, the one-month column is the honest place to start, and what actually happens to digestion on these drugs is the background reading.

Where it lands

On its GLP-1 line, Trellis Vitality is one of the two or three best-documented operators in this batch: a real table, a named pharmacy, a verifiable medical director, and a competitive month-to-month rung. On everything else, it publishes a starting price and asks you to trust that the rest is reasonable.

We do not take a commission from Trellis, and there is no tracking link in this article. If you want to see how the same test lands on other operators, Pepti publishes lower and contradicts itself in its own data, Auren Rx publishes an explicit no-commitment rung on every product but never says which states it serves, and Rehydra+ Wellness publishes a monthly figure you cannot buy for one month. None of these is a program this site links out to. The ones that are get the same test applied to them and are ordered by how much each will tell you before you commit, in our GLP-1 telehealth ranking.